Status:
COMPLETED
Radiomics to Identify Patients at Risk for Developing Pneumonitis, Differentiate Immune Checkpoint Inhibitor-induced Pneumonitis From Other Lung Inflammation and Distinguish Tumour Pseudo-progression From Real Tumour Growth
Lead Sponsor:
Maastricht Radiation Oncology
Collaborating Sponsors:
Maastricht University Medical Center
Zuyderland Medical Centre
Conditions:
Stage IV Non-small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Brief Summary
The investigators will develop a radiomics signature for immune checkpoint-induced pneumonitis in 40 patients with a pulmonary event under anti-PD1 or anti-PD-L1 (cases) and 40 patients without a pulm...
Detailed Description
Preliminary analyses on a dataset showed a clear distinction in radiomics features for patients with and without pneumonitis from anti-PD1 or anti-PD-L1. Prior experience of the investigators of train...
Eligibility Criteria
Inclusion
- Patients who receive standard anti-PD1 or anti-PD-L1 treatment in routine clinical practice for first or second line stage IV non-small cell lung cancer
Exclusion
- The opposite of the above
Key Trial Info
Start Date :
September 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2021
Estimated Enrollment :
637 Patients enrolled
Trial Details
Trial ID
NCT03305380
Start Date
September 1 2017
End Date
April 1 2021
Last Update
September 16 2021
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Zuyderland Medical Center
Heerlen, Netherlands, 6419 PC
2
MUMC+
Maastricht, Netherlands, 6229 HX